Divi's Labs profit up 80.61 percent to Rs 492.06 crore in Q1

Published On 2020-08-10 04:30 GMT   |   Update On 2021-08-13 16:03 GMT

New Delhi: Shares of Divi's Laboratories on Monday rallied over 18 per cent after the company reported 80.61 per cent rise in consolidated net profit for June quarter 2020. The stock jumped 15.93 per cent to a one-year high of Rs 3,228.05 on the BSE.On the NSE, it gained 18.24 per cent to a 52-week high of Rs 3,293.The drug firm on Saturday reported 80.61 per cent rise in consolidated net...

Login or Register to read the full article

New Delhi: Shares of Divi's Laboratories on Monday rallied over 18 per cent after the company reported 80.61 per cent rise in consolidated net profit for June quarter 2020. The stock jumped 15.93 per cent to a one-year high of Rs 3,228.05 on the BSE.

On the NSE, it gained 18.24 per cent to a 52-week high of Rs 3,293.
The drug firm on Saturday reported 80.61 per cent rise in consolidated net profit at Rs 492.06 crore for June quarter 2020 mainly on account of robust sales.  
The company had logged a profit of Rs 272.44 crore in the year-ago same period, Divi's Laboratories said in a filing to BSE.
Total income of the company stood at Rs 1,747.80 crore dring the quarter under review as against Rs 1,193.20 crore in April-June 2019-20, it added.
"The company has been able to have near normal operations during the quarter and there was minimal impact due to COVID-19 pandemic," Divi's Laboratories said.

Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News